CTIC | CTI BioPharma (NASDAQ:CTIC) Coverage Initiated by Analysts at Brookline Capital Management

Brookline Capital Management began coverage on shares of CTI BioPharma (NASDAQ:CTIC) in a research note issued to investors on Friday, The Fly reports.The firm issued a buy rating and a $7.00 price target on the biopharmaceutical company’s stock.Several other research analysts have also recently weighed in on the company.Lake Street Capital restated […]Transcript Daily